← All trials
NCT04883333
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2021
- Primary completion
- Jan 29, 2022
- Completion date
- Jan 29, 2022
- First posted
- May 12, 2021
- Last posted
- Jun 2, 2021
- Enrollment
- 122
- Arms / groups
- 15 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Leo PharmaLead sponsor
- Leo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.